ABX SA

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Doubles Down On Metabolic Disorde

It took Eli Lilly & Co. only about three months to take its animal health business public after announcing in July that it planned to spin out Elanco as a separate company, and now Lilly has a new b

Endocyte Inc. intends to use a deal to acquire worldwide rights for the prostate cancer therapeutic 177 Lu-PSMA-617 from ABX SA in Germany as a springboard for building a pipeline of radioligand